Learn more

AVIXGEN INC

Overview
  • Total Patents
    60
  • GoodIP Patent Rank
    34,950
  • Filing trend
    ⇩ 22.0%
About

AVIXGEN INC has a total of 60 patent applications. It decreased the IP activity by 22.0%. Its first patent ever was published in 2000. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are DCB-USA LLC, KITHER BIOTECH S R L and SLOAN KETTERING INST CANCER.

Patent filings per year

Chart showing AVIXGEN INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Baek Yi Yong 36
#2 Koo Hye Cheong 22
#3 Choi Jun Sub 21
#4 Kim Min Jung 18
#5 You Ji Chang 14
#6 Han Gyoon Hee 9
#7 Song Doo Na 9
#8 Lee Chul Ho 9
#9 Chung Koo Hwan 9
#10 Kim Young Myeong 7

Latest patents

Publication Filing date Title
KR20200011900A Pharmaceutical Composition for Preventing, ameliorating or Treating Osteoarthritis Comprising Rhodanine Derivatives as an Active Ingredient
EP3808842A1 Pharmaceutical composition for treating severe complex immunodeficiency comprising fusion protein of cell penetrating peptide and adenosine deaminase
WO2019240431A1 Pharmaceutical composition comprising fusion protein of cell-penetrating peptide and rpe65 for treatment of leber's congenital amaurosis
EP3808762A1 Fusion protein bound to cell-permeable peptide, and composition comprising fusion protein or cell-permeable peptide and epithelial cell growth factor as active ingredients
KR101893988B1 Pharmaceutical composition comprising Rhodanine derivative for preventing or treating AIDS
KR101933217B1 Peptide for Inhibiting Skin Inflammation And Composition for Preventing or Treating Skin Inflammation Containing The Same
WO2018111051A1 Cytoplasmic transduction peptide and intracellular messenger comprising same
CA3045599A1 Cytoplasmic transduction peptide and intracellular messenger comprising same
KR20180130895A A Pharmaceutical Composition for Preventing or Treating AIDS
US2018193339A1 Pharmaceutical composition for preventing and treating dry eye diseases, containing imatinib as active ingredient
KR101644440B1 Peptides having improved anti-angiogenic effect and pharmaceutical composition containing them for preventing or treating angiogenesis-related diseases including cancer, diabetic retinopathy or age-related macular degeneration
KR101676690B1 Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof
KR20120115481A Novel thiourea or urea derivative, process for preparing the same and pharmaceutical composition for preventing or treating aids comprising the same
KR20110137939A Novel rhodanine derivative, process for preparing the same and pharmaceutical composition for preventing or treating aids comprising the same
KR20110137941A Novel thiourea or urea derivative, process for preparing the same and pharmaceutical composition for preventing or treating aids comprising the same
WO2008105604A1 Recombinant mammalian cell for screening a substance preventing and treating aids and screening method using the same
KR20040034278A Process for Preparing Nucleocapsid Protein of HIV in Mammalian Cell
KR20030092440A Method for Remote Diagnosis of AIDS
KR20030018483A RNA Which Binds to HIV-1 Nucleocapsid
KR20020052766A Method for Remote Diagnosis of Diseases Via Telecommunication System